The first medical trial of the psychedelic drug LSD in more than 40 years showed overwhelmingly helpful results for terminally ill patients.
Conducted by researchers in Switzerland, the double-blind study gave either full doses or small (placebo) doses of lysergic acid diethylamide (LSD) to 12 terminally ill patients along with drug-free psychotherapy sessions.
The study found “statistically significant reductions in anxiety associated with advanced stage illness,” said Brad Burge, Director of Communications for the Multidisciplinary Association for Psychedelic Studies (MAPS).
The study found the patients who took LSD had less anxiety about facing death, and that feeling continued long after they took the drug.
“My LSD experience brought back some lost emotions and ability to trust, lots of psychological insights and a timeless moment when the universe didn’t seem like a trap, but like a revelation of utter beauty,” said Peter, a participant in the study.
The LA Times reports the study, published March 4, was the first of its kind in more than four decades.
“This study is historic and marks a rebirth of investigation into LSD-assisted psychotherapy,” says Rick Doblin, Ph.D., MAPS Executive Director. “The positive results and evidence of safety clearly show why additional, larger studies are needed.”